Gyros Protein Technologies introduces Gyrolab Generic Anti-AAV Kit to support gene therapy development Post author: Post published:June 17, 2024 Post category:uncategorized Ready-to-use kit enables detection of binding antibodies against AAV vectors without the need for serotype-specific assays. You Might Also Like NUS researchers develop DNA barcoded nanoparticles for targeted cancer therapy January 24, 2025 Study finds strong evidence that bird flu spreads through the air between farms February 24, 2025 Drug effects on gut microbiome altered by bacterial communities September 24, 2024